Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

作者：Homie Razavi, Imam Waked, Huma Qureshi, Loreta A. Kondili, Ann‐Sofi Duberg, Soo Aleman, Junko Tanaka, Jeffrey V. Lazarus, Daniel Low‐Beer, Zaigham Abbas, Antoine Abou Rached, Alessio Aghemo, Inka Aho, Ulus Salih Akarca, Said A. Al‐Busafi, Waleed K. Al‐Hamoudi, Khalid Al‐Naamani, Ahmed Sabry Alaama, Manahil M Aldar, Mohammed Alghamdi, Mónica Alonso González, Haleema Alserehi, Anil C. Anand, Tarik Asselah, Abdullah M. Assiri, Kostas Athanasakis, Rita Atugonza, Ziv Ben‐Ari, Thomas Berg, Carlos Eduardo Brandão‐Mello, A. Brown, Kimberly Brown, Robert S. Brown, Philip Bruggmann, Maurizia Rossana Brunetto, María Buti, Hugo Cheinquer, Peer Brehm Christensen, Vladimir Chulanov, Laura Garza, Carla S. Coffin, Nicola Coppola, Antonio Craxı̀, Javier Crespo, Fuqiang Cui, Olav Dalgård, Alethse de la Torre, Victor de Lédinghen, Douglas T. Dieterich, Sylvia Dražilová, Jean‐François Dufour, Mohamed El‐Kassas, Mohammed Elbadri, Gamal Esmat, Rafael Esteban Mur, Brandon Eurich, Diana Faini, Paulo Roberto Abrão Ferreira, Robert Flisiak, Soňa Fraňková, Giovanni Battista Gaeta, Ivane Gamkrelidze, Edward Gane, Virginia Garcia, Javier García‐Samaniego, Manik Gemilyan, Magnús Gottfreðsson, Michael Gschwantler, Ana Paula Maciel Gurski, Behzad Hajarizadeh, Saeed Hamid, Angelos Hatzakis, Julian Hercun, Ivana Hockicková, Jee‐Fu Huang, Béla Hunyady, Sharon Hutchinson, Naoko Ishikawa, Kiyohiko Izumi, Antonio Izzi, Martin Janíčko, Peter Jarčuška, Agita Jēruma, Asgeir Johannessen, Kulpash Kaliaskarova, Jia‐Horng Kao, Knut Boe Kielland, Nicolas Kodjoh, Shyamasundaran Kottilil, Pavol Kristián, Paul Y. Kwo, Martin Lagging, Hilton Y. Lam, Pablo Lázaro, Mei‐Hsuan Lee, Sabela Lens, Valentina Liakina, Young‐Suk Lim, Michael Makara, M.P. Manns, Casimir Manzengo, Sadik Memon, Maria Cássia Mendes-Corrêa, Vincenzo Messina, Håvard Midgard, Niamh Murphy, Erkin Musabaev, Marcelo Contardo Moscoso Naveira, H. Nde, Francesco Negro, Nirada Nim, Ponsiano Ocama, Sigurður Ólafsson, C. Omuemu, Javier Pamplona, Calvin Q. Pan, George Papatheodoridis, Nikolay Pimenov, Hossein Poustchi, Maria Giovanna Quaranta, Alnoor Ramji, Henna Rautiainen, Devin Razavi‐Shearer, Kathryn Razavi‐Shearer, Ezequiel Ridruejo, Cielo Ríos, Shakhlo Sadirova, Faisal M. Sanai, Christoph Sarrazin, Gulya Sarybayeva, Ivan Schréter, Carole Seguin‐Devaux, Leandro Soares Sereno, Gamal Shiha, Josie Smith, Riham Soliman, Mark Sonderup, C Wendy Spearman, Rudolf Stauber, Catherine Stedman, Vana Sypsa, Frank Tacke, Norah A. Terrault, Ieva Tolmane, Berend Van Welzen, Alexis Voeller, Yasir Waheed, Carolyn Wallace, Robert Whittaker, Vincent Wai‐Sun Wong, Magdalena Ydreborg, Kakharman Yesmembetov, Ming‐Lung Yu, Stefan Zeuzem, Eli Zuckerman · 发表于：Journal of Hepatology · 年份：2025 · DOI：10.1016/j.jhep.2025.01.013 · 被引用次数：24 · 研究领域：Hepatitis C virus research、Hepatitis B Virus Studies、Pharmaceutical Economics and Policy

BACKGROUND & AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV). Monitoring HCV treatment trends by country, region, and globally is important to assess progress toward the World Health Organization's 2030 elimination targets. Additionally, historical patterns can help predict the uptake of future therapies for other liver diseases. METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used. RESULTS: An estimated 13,816,000 (95% uncertainty intervals: 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program. CONCLUSIONS: ...